| 000 | 01579 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517185319.0 | ||
| 264 | 0 | _c20180816 | |
| 008 | 201808s 0 0 eng d | ||
| 022 | _a1744-8301 | ||
| 024 | 7 |
_a10.2217/fon-2017-0491 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBan, Marija | |
| 245 | 0 | 0 |
_aEfficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer. _h[electronic resource] |
| 260 |
_bFuture oncology (London, England) _cMar 2018 |
||
| 300 |
_a537-544 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPiperazines _xadministration & dosage |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xmetabolism |
| 650 | 0 | 4 |
_aReceptors, Estrogen _xmetabolism |
| 650 | 0 | 4 |
_aReceptors, Progesterone _xmetabolism |
| 650 | 0 | 4 | _aRetreatment |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMiše, Branka Petrić | |
| 700 | 1 | _aMajić, Ana | |
| 700 | 1 | _aDražić, Ivanka | |
| 700 | 1 | _aVrdoljak, Eduard | |
| 773 | 0 |
_tFuture oncology (London, England) _gvol. 14 _gno. 6 _gp. 537-544 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/fon-2017-0491 _zAvailable from publisher's website |
| 999 |
_c27814849 _d27814849 |
||